Navigation Links
ISPE Announces Nancy Berg as New CEO and President Succeeding Bob Best Effective 1 January

TAMPA, Fla., Jan. 3, 2012 /PRNewswire/ -- ISPE, the International Society for Pharmaceutical Engineering, today announced the appointment of Nancy S. Berg as president and CEO, effective 1 January 2012.

Berg brings 30 years of experience in strategic leadership, organizational growth and relationship-building, having served as executive director/CEO of the Society of Manufacturing Engineers (SME) and, most recently, as the founder and owner of three small businesses and consultant to both non-profits and for-profits.

At the helm of SME, Berg led the development of SME's strategic plan, Plan 2010, and the expansion of its technical networks. Through these and other forward-thinking initiatives, she prepared the organization for changes in industry business models, competitive forces and the impact of globalization.

Berg's selection by the SME Board of Directors as executive director in 2000 made her the youngest person to head a global engineering/technical organization at the time. Prior to that, she held other domestic and international positions where she gained experience that will also benefit ISPE. For example, she facilitated dialog, joint ventures and coalitions with other trade groups, associations, companies, governments and agencies. She brings to ISPE these relationship-building skills and links to industries and associations.

"Berg's demonstrated ability to anticipate industry changes, set a vision for success, then lead coordinated, dynamic efforts to achieve this plan make her the ideal person to drive us in achieving our mission," said 2012 ISPE Board Chairman Arthur "Randy" Perez. 

"As the voice of pharmaceutical engineering and manufacturing communities, ISPE is dedicated to working with Members and their companies to resolve issues and drive their understanding and use of next-generation manufacturing practices," continued Perez. "Berg's appointment comes at a time when the global pharmaceutical industry faces increased pressure to improve productivity and control costs across their product development and manufacturing operations. She brings the right blend of knowledge and leadership experience to guide us in enhancing our value to our Members, our relevance to the industry, and our role as a catalyst for solutions that will positively influence global health."

Berg replaces Bob Best, who resigned his position effective Dec. 31 after a 27-year career with the Society. Best will remain involved in the organization as a consultant through the end of 2012.

Karen Manardo
Manardo Communications, LLC
Tel: +1-313-671-1085

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)...  Six months of adjunctive metformin therapy does not improve ... to new research from T1D Exchange and funded ... beneficial effect on measures of obesity, including weight and BMI. ... Journal of the American Medical Association , are from the ... on overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday 27 Oct 2015, ... educate the personnel on spinal decompression therapy and offer his professional help. , ... The benefits come from creating negative intradiscal pressure which is conducive to retraction ...
(Date:12/1/2015)... ... 01, 2015 , ... World Patent Marketing , a vertically integrated ... allows for easier packing and organizing of items into one big, portable jar. , ... Cooper, CEO and Creative Director of World Patent Marketing and Desa Industries Inc ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article ... a discrimination claim against the U.S. Department of Health and Human Services, claiming that ... (ACA) plans are breaking the clause in the law prohibiting the denial of coverage ...
(Date:12/1/2015)... Los Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... the United States, today announced that its iconic bottle has won top honors in ... drinks category. The Company also announced that it has been selected as a ...
Breaking Medicine News(10 mins):